Syensqo (SYENS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Apr, 2026Executive summary
CEO outlined a new strategic direction focused on value creation, operational excellence, innovation, and disciplined capital deployment.
Leadership changes included a new Chief People Officer and ongoing searches for Chief Operations and Chief Strategy Officers.
The company completed its separation from Solvay, exited transition service agreements, and divested the Oil & Gas business, with plans to divest the Aroma business in 2026.
Shareholder returns increased 22% year-over-year, with €120 million in share repurchases and a proposed dividend of €1.62 per share.
2025 saw resilient cash generation and margin performance despite challenging demand and macroeconomic conditions, with a focus on cost discipline and innovation-driven growth.
Financial highlights
Full-year 2025 net sales were €5.76 billion, down 6.5% year-over-year, mainly due to lower volumes in Specialty Polymers and Electronics.
Underlying EBITDA was €1.19 billion, down 14% year-over-year, with a margin of 20.6%.
Free cash flow reached €356 million, up 60% from 2024, supported by disciplined capital deployment and strong cash conversion (76%).
Net profit attributable to shareholders was €381 million, a 31% decrease year-over-year; underlying EPS was €3.72.
Capex reduced 16% year-over-year to €563 million.
Outlook and guidance
2026 is expected to see a return to volume growth, led by Composite Materials and civil aerospace, with gradual recovery in semiconductors in H2.
Underlying EBITDA for 2026 is guided at approximately €1.1 billion, with operating cash flow around €700 million and capex below €500 million.
Cost savings of over €200 million targeted by end of 2026 to offset inflation.
Q1 2026 EBITDA is expected to be similar to Q4 2025, reflecting a slow start across several end markets.
Foreign exchange is expected to be a €40 million headwind to EBITDA.
Latest events from Syensqo
- Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025 - Q1 2025 EBITDA down 15% year-over-year; 2025 outlook and cost-saving targets reaffirmed.SYENS
Q1 202519 Nov 2025